ClinicalTrials.gg
CompletedNCT02504320Updated Jan 19, 2017Results posted

Phase 1, Febuxostat XR Relative Bioavailability Study

A Phase 1 interventional study of Febuxostat XR 80 mg Capsule F1 and Febuxostat XR 80 mg Capsule F2 in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-19.

Sponsored by Takeda · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will assess the relative bioavailability, safety and tolerability following administration of 80 mg single oral doses of 4 febuxostat extended release (XR) formulations.

Read the detailed description

The drug being tested is this study is febuxostat XR. Four different formulations of febuxostat XR are being tested to see how the drug moves through the body. This study will look at safety and side effects in people who take febuxostat XR.

This cross-over study will enroll approximately 78 patients. Participants will be randomly assigned to 1of 4 sequences which will determine the order of the 4 treatments received:

  • Febuxostat XR 80 mg capsule Formulation 1
  • Febuxostat XR 80 mg capsule Formulation 2
  • Febuxostat XR 80 mg capsule Formulation 3
  • Febuxostat XR 80 mg capsule Formulation 4

Participants will take 1 dose on Day 1 with a washout period between each period.

This single-center trial will be conducted in the United States. The overall time to participate in this study is up to 80 days. Participants will make multiple visits to the clinic including a period of confinement, and will be contacted by telephone 30 days after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures including requesting that a participant fast for any laboratory evaluations.
  3. Is a healthy male or female and aged 18 to 55 years, inclusive, at the time of informed consent and first study medication dose.
  4. Weighs at least 50.0 kg and has a (BMI) from 18.0 to 30.0 kg/m2, inclusive at Screening.
  5. A male participant who is nonsterilized and sexually active with a female partner of agrees to use adequate from signing of informed consent throughout the duration of the study and for 30 days after the last dose.
  6. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent,
  7. Is willing to refrain from strenuous exercise from Day -1 of Period 1 until Study Exit (Day 3 of Period 4).
  8. Has estimated (eGFR) ≥90 mL/min at Screening and Check-in (Day -1 of Period 1).

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 30 days prior to the first dose of study medication.
  2. Has received febuxostat in a previous clinical study or as a therapeutic agent.
  3. Is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in the conduct of this study.
  4. Has uncontrolled, (CS) disease or other abnormality, which may impact the ability of the participant to participate or potentially confound the study results.
  5. Has a known to any component of the formulation of XO inhibitors, xanthine compounds, caffeine, or any component of the formulation of febuxostat capsules.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Treatment Sequence ABDC

    Febuxostat XR 80 mg capsule Formulation 1 (F1), orally, once on Day 1 of Period 1 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 2 (F2), orally, once on Day 1 of Period 2 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 4 (F4), orally, once on Day 1 of Period 3 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 3 (F3), orally, once on Day 1 of Period 4 (C).

    Drug: Febuxostat XR 80 mg Capsule F1 · Drug: Febuxostat XR 80 mg Capsule F2 · Drug: Febuxostat XR 80 mg Capsule F3 · Drug: Febuxostat XR 80 mg Capsule F4

  • Experimental
    Treatment Sequence DACB

    Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 1 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1 orally, once on Day 1 of Period 2 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 3 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 4 (B).

    Drug: Febuxostat XR 80 mg Capsule F1 · Drug: Febuxostat XR 80 mg Capsule F2 · Drug: Febuxostat XR 80 mg Capsule F3 · Drug: Febuxostat XR 80 mg Capsule F4

  • Experimental
    Treatment Sequence CDBA

    Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 1 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4 orally, once on Day 1 of Period 2 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 3 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 4 (A).

    Drug: Febuxostat XR 80 mg Capsule F1 · Drug: Febuxostat XR 80 mg Capsule F2 · Drug: Febuxostat XR 80 mg Capsule F3 · Drug: Febuxostat XR 80 mg Capsule F4

  • Experimental
    Treatment Sequence BCAD

    Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 1 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3 orally, once on Day 1 of Period 2 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 3 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 4 (D).

    Drug: Febuxostat XR 80 mg Capsule F1 · Drug: Febuxostat XR 80 mg Capsule F2 · Drug: Febuxostat XR 80 mg Capsule F3 · Drug: Febuxostat XR 80 mg Capsule F4

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Cmax: Maximum Observed Plasma Concentration for Febuxostat

    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose

  2. Mean AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Febuxostat

    AUCt is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration.

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose

  3. Mean AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat

    AUC∞ is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose

07

Results

Posted Jan 19, 2017

Participant flow

Participants took part in the study at 1 investigative site in the United States from 29 June 2015 to 01 October 2015.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneTreatment Sequence ABDCTreatment Sequence DACBTreatment Sequence CDBATreatment Sequence BCAD
Started19192020
Completed19191920
Not completed0010
Withdrew: Positive drug screen0010
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneTreatment Sequence ABDCTreatment Sequence DACBTreatment Sequence CDBATreatment Sequence BCAD
Started19191920
Completed19181920
Not completed0100
Withdrew: Positive drug screen0100
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneTreatment Sequence ABDCTreatment Sequence DACBTreatment Sequence CDBATreatment Sequence BCAD
Started19181920
Completed19181819
Not completed0011
Withdrew: Positive drug screen0001
Withdrew: Adverse event0010
Treatment Period 4
Participant flow — Treatment Period 4
MilestoneTreatment Sequence ABDCTreatment Sequence DACBTreatment Sequence CDBATreatment Sequence BCAD
Started19181819
Completed19181819
Not completed0000

Outcome measures

PrimaryMean Cmax: Maximum Observed Plasma Concentration for Febuxostat

Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Reported as:
Mean · ng/mL
Mean Cmax: Maximum Observed Plasma Concentration for Febuxostat
ng/mLRegimen A: Febuxostat XR 80 mg Formulation 1Regimen B: Febuxostat XR 80 mg Formulation 2Regimen C: Febuxostat XR 80 mg Formulation 3Regimen D: Febuxostat XR 80 mg Formulation 4
Mean Cmax: Maximum Observed Plasma Concentration for Febuxostat2027.1184 ± 1278.283681442.2267 ± 991.945831730.2468 ± 1013.562041809.3158 ± 1170.53245
Statistical analysis
  • Regimen A: Febuxostat XR 80 mg Formulation 1 vs Regimen D: Febuxostat XR 80 mg Formulation 4 · Point estimate: 1.0848 · 90% CI 0.9528 to 1.2350Point estimate and 90% CI were obtained from the exponentiated results of analysis of the natural log (ln)-transformed parameters was performed with regimen, sequence, period, and participants nested within sequence as fixed effects.
  • Regimen B: Febuxostat XR 80 mg Formulation 2 vs Regimen D: Febuxostat XR 80 mg Formulation 4 · Point estimate: 0.7709 · 90% CI 0.6767 to 0.8782Point estimate and 90% CI were obtained from the exponentiated results of analysis of the natural log (ln)-transformed parameters was performed with regimen, sequence, period, and participants nested within sequence as fixed effects.
  • Regimen C: Febuxostat XR 80 mg Formulation 3 vs Regimen D: Febuxostat XR 80 mg Formulation 4 · Point estimate: 0.9389 · 90% CI 0.8246 to 1.0689Point estimate and 90% CI were obtained from the exponentiated results of analysis of the natural log (ln)-transformed parameters was performed with regimen, sequence, period, and participants nested within sequence as fixed effects.
PrimaryMean AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Febuxostat

AUCt is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration.

Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Reported as:
Mean · ng*hr/mL
Mean AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Febuxostat
ng*hr/mLRegimen A: Febuxostat XR 80 mg Formulation 1Regimen B: Febuxostat XR 80 mg Formulation 2Regimen C: Febuxostat XR 80 mg Formulation 3Regimen D: Febuxostat XR 80 mg Formulation 4
Mean AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Febuxostat9395.6014 ± 3961.552037971.0624 ± 3291.363908652.7080 ± 3673.916668817.3600 ± 3429.94880
Statistical analysis
  • Regimen A: Febuxostat XR 80 mg Formulation 1 vs Regimen D: Febuxostat XR 80 mg Formulation 4 · Point estimate: 1.0435 · 90% CI 0.9840 to 1.1066Point estimate and 90% CI were obtained from the exponentiated results of analysis of the natural log (ln)-transformed parameters was performed with regimen, sequence, period, and participants nested within sequence as fixed effects.
  • Regimen B: Febuxostat XR 80 mg Formulation 2 vs Regimen D: Febuxostat XR 80 mg Formulation 4 · Point estimate: 0.8777 · 90% CI 0.8274 to 0.9311Point estimate and 90% CI were obtained from the exponentiated results of analysis of the natural log (ln)-transformed parameters was performed with regimen, sequence, period, and participants nested within sequence as fixed effects.
  • Regimen C: Febuxostat XR 80 mg Formulation 3 vs Regimen D: Febuxostat XR 80 mg Formulation 4 · Point estimate: 0.9540 · 90% CI 0.8996 to 1.0117Point estimate and 90% CI were obtained from the exponentiated results of analysis of the natural log (ln)-transformed parameters was performed with regimen, sequence, period, and participants nested within sequence as fixed effects.
PrimaryMean AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat

AUC∞ is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.

Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Reported as:
Mean · ng*hr/mL
Mean AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat
ng*hr/mLRegimen A: Febuxostat XR 80 mg Formulation 1Regimen B: Febuxostat XR 80 mg Formulation 2Regimen C: Febuxostat XR 80 mg Formulation 3Regimen D: Febuxostat XR 80 mg Formulation 4
Mean AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat9368.0744 ± 3944.012808278.6143 ± 3205.315568938.8765 ± 3746.601539102.3700 ± 3430.45699
Statistical analysis
  • Regimen A: Febuxostat XR 80 mg Formulation 1 vs Regimen D: Febuxostat XR 80 mg Formulation 4 · Point estimate: 1.0283 · 90% CI 0.9691 to 1.0911Point estimate and 90% CI were obtained from the exponentiated results of analysis of the natural log (ln)-transformed parameters was performed with regimen, sequence, period, and participants nested within sequence as fixed effects.
  • Regimen B: Febuxostat XR 80 mg Formulation 2 vs Regimen D: Febuxostat XR 80 mg Formulation 4 · Point estimate: 0.9056 · 90% CI 0.8516 to 0.9630Point estimate and 90% CI were obtained from the exponentiated results of analysis of the natural log (ln)-transformed parameters was performed with regimen, sequence, period, and participants nested within sequence as fixed effects.
  • Regimen C: Febuxostat XR 80 mg Formulation 3 vs Regimen D: Febuxostat XR 80 mg Formulation 4 · Point estimates: 0.9463 · 90% CI 0.8909 to 1.0051Point estimate and 90% CI were obtained from the exponentiated results of analysis of the natural log (ln)-transformed parameters was performed with regimen, sequence, period, and participants nested within sequence as fixed effects.

Adverse events

Collected over From the first administration of study drug on Day 1 of Period 1 up to 30 days after the last dose of study drug or Early termination visit (approximately up to 95 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regimen A: Febuxostat XR 80 mg Formulation 1—0/76 (0%)6/76 (7.9%)
Regimen B: Febuxostat XR 80 mg Formulation 2—1/76 (1.3%)9/76 (11.8%)
Regimen C: Febuxostat XR 80 mg Formulation 3—0/77 (0%)7/77 (9.1%)
Regimen D: Febuxostat XR 80 mg Formulation 4—0/76 (0%)7/76 (9.2%)
Most frequent serious events
Most frequent serious events
EventRegimen A: Febuxostat XR 80 mg Formulation 1Regimen B: Febuxostat XR 80 mg Formulation 2Regimen C: Febuxostat XR 80 mg Formulation 3Regimen D: Febuxostat XR 80 mg Formulation 4
Blood creatine phosphokinase increasedInvestigations0/761/760/770/76
Most frequent other events
Showing 10 of 21
Most frequent other events
EventRegimen A: Febuxostat XR 80 mg Formulation 1Regimen B: Febuxostat XR 80 mg Formulation 2Regimen C: Febuxostat XR 80 mg Formulation 3Regimen D: Febuxostat XR 80 mg Formulation 4
HeadacheNervous system disorders1/762/761/773/76
NasopharyngitisInfections and infestations0/762/760/770/76
DiarrhoeaGastrointestinal disorders0/760/762/770/76
NauseaGastrointestinal disorders1/760/760/771/76
VomitingGastrointestinal disorders0/761/760/770/76
Bacterial vaginosisInfections and infestations1/760/760/770/76
Oral herpesInfections and infestations0/760/760/771/76
TrichomoniasisInfections and infestations0/761/760/770/76
ContusionInjury, poisoning and procedural complications0/760/760/771/76
Back painMusculoskeletal and connective tissue disorders1/761/760/770/76

Baseline characteristics

Safety Set included all participants who were enrolled and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Treatment Sequence ABDCTreatment Sequence DACBTreatment Sequence CDBATreatment Sequence BCADTotal
Mean31.7 ± 7.5630.7 ± 6.5134.0 ± 8.8731.2 ± 7.7831.9 ± 7.70
Gender
Gender(Participants)Treatment Sequence ABDCTreatment Sequence DACBTreatment Sequence CDBATreatment Sequence BCADTotal
Female101091443
Male9911635
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment Sequence ABDCTreatment Sequence DACBTreatment Sequence CDBATreatment Sequence BCADTotal
Hispanic or Latino11791037
Not Hispanic or Latino812111041
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment Sequence ABDCTreatment Sequence DACBTreatment Sequence CDBATreatment Sequence BCADTotal
Asian00011
Black or African American476623
White1511141353
Multiracial01001
Region of Enrollment
Region of Enrollment(Participants)Treatment Sequence ABDCTreatment Sequence DACBTreatment Sequence CDBATreatment Sequence BCADTotal
United States1919202078
Height
Height(cm)Treatment Sequence ABDCTreatment Sequence DACBTreatment Sequence CDBATreatment Sequence BCADTotal
Mean167.6 ± 10.13171.1 ± 11.75167.5 ± 9.70165.7 ± 6.67167.9 ± 9.71
Weight
Weight(kg)Treatment Sequence ABDCTreatment Sequence DACBTreatment Sequence CDBATreatment Sequence BCADTotal
Mean72.98 ± 12.68579.05 ± 11.84671.22 ± 12.35069.72 ± 11.01573.17 ± 12.273
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Treatment Sequence ABDCTreatment Sequence DACBTreatment Sequence CDBATreatment Sequence BCADTotal
Mean25.84 ± 2.66326.98 ± 2.72225.29 ± 3.16825.28 ± 2.80225.83 ± 2.878

5 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Austin, Texas 78744, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Sep 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2015
First posted
Jul 21, 2015
Start
Aug 2015
Primary completionActual
Sep 2015
CompletionActual
Oct 2015
Results first posted
Jan 19, 2017
Last update
Jan 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02504320
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 21, 2015
Start date
Aug 2015
Primary completion
Sep 2015
Completion
Oct 2015
Results posted
Jan 19, 2017
Last update
Jan 19, 2017

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion